Highest-materiality recent filing
Nephros Q1 net revenue up 7% to $5.2M; net income falls to $140K; tariffs hit margins
Net revenue $5.2M (+7% YoY); programmatic revenue up 23% YoY.
Replaces prior Dec 2023 License & Supply Agreement with Medica; that agreement terminated.
Net revenue $4.4M, up 36% YoY from $3.3M; net income $237k vs net loss $289k.
Nephros Q1 2025 revenue $4.9M (+38% YoY), net income $558K, adjusted EBITDA $667K
Net revenue $4.9M, up 38% from $3.5M in Q1 2024; core programmatic revenue grew 23%.
Nephros reports first annual net income; Q4 revenue up 19% YoY to $3.9M
Net income of $74K for FY2024 vs net loss of $1.6M in 2023; first annual profit in company history.
Nephros posts Q3 net income of $0.2M, first profitable quarter; revenue $3.5M
Net revenue $3.5M, down 6% YoY but up 8% from Q2 2024.
Nephros Q1 revenue down 5% to $3.5M; net loss narrows to $0.2M
Net revenue $3.5M, down 5% YoY, but programmatic (recurring non-ER) business grew 12% YoY.
Nephros FY2023 revenue up 43% to $14.2M; net loss narrows to $1.6M from $4.3M
Full-year net revenue from continuing ops $14.2M, up 43% YoY; Q4 revenue $3.3M, up 27%.
On April 23, 2025, Alisa Lask notified the Board of Directors (the “Board”) of Nephros, Inc. (the “Company”) that she will not stand for re-election to the Board at the Company’s annual meeting of stockholders scheduled to be held on June 16, 2025 (the “2025 Annual Meeting”).
Max materiality 0.75 · Median 0.55 · Most common event earnings